# Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06128837/  
OnCo record `nct06128837` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Topotecan in small-cell lung cancer, run by Luye Pharma Group Ltd., now recruiting.

## Summary

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06128837 by Luye Pharma Group Ltd., with 686 participants planned, started 2024-03-03 and due to reach its primary completion in 2028-06. Interventions recorded: Irinotecan hydrochloride liposome Injection, Topotecan. Conditions listed: Relapsed Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06128837
- Phase: 3
- Setting: A Multicenter, Randomized, Open-label, Parallel-design Phase 3 Study to Evaluate the Efficacy and Safety of LY01610 (Irinotecan Hydrochloride Liposome Injection) Versus Topotecan in Patients With Recurrent Small Cell Lung Cancer (SCLC)
- Sponsor: Luye Pharma Group Ltd.
- Enrolled: 686

## Sources

- ClinicalTrials.gov NCT06128837: https://clinicaltrials.gov/study/NCT06128837

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Topotecan](https://onco.cc/drugs/topotecan/)
- companies: [Luye Pharma Group](https://onco.cc/companies/luye-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06128837.json